In late January, a bill to amend the Pharmaceuticals and Medical Devices Act cleared key legislation review processes by the…
REGULATORY
PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
Japan will launch a registration trial process for Fujifilm Toyama Chemical’s anti-flu drug Avigan (favipiravir) for the treatment of the novel coronavirus disease COVID-19, Prime Minister Shinzo Abe said at a televised news conference on March 28. Currently, Avigan is…
To read the full story
Related Article
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
REGULATORY
- J&J’s Lazcluze, Genmab’s Tivdak, and More Up for MHLW Panel Review on Feb. 27
February 14, 2025
- Japan Cabinet Approves Bill to Amend PMD Act
February 13, 2025
- MHLW Not Yet Able to Examine Letters of Protest by US Lobbies: Minister
February 13, 2025
- Set Deadline for Non-Prescription Pilot of Morning-After Pill: Panel Members
February 13, 2025
- MHLW Panel Wary of Non-Prescription Switches for Diquas, Mucosta
February 13, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…